Affordable Access

Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer.

Authors
Type
Published Article
Journal
Asian Pacific journal of cancer prevention : APJCP
Publication Date
Volume
15
Issue
13
Pages
5343–5348
Identifiers
PMID: 25040999
Source
Medline
License
Unknown

Abstract

The addition of trstuzumab MoAb to chemotherapy for gastric and gastroesophageal cancer significantly improved outcome of OS and PFS endpoints, while other MoAbs led to no improvement in results. Some adverse events were increased in anti-HER MoAbs arm compared with the control.

Statistics

Seen <100 times